BENOQUIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BENOQUIN (BENOQUIN).
Selective DNA gyrase inhibitor in bacteria; also inhibits topoisomerase IV.
| Metabolism | Hepatic via CYP450 (minimal); primarily excreted unchanged renally. |
| Excretion | BENOQUIN (benoquinate) is primarily excreted renally as unchanged drug (65-70%) and glucuronide conjugates (20-25%); less than 5% eliminated via feces. |
| Half-life | Terminal elimination half-life is 6-8 hours. In elderly or patients with renal impairment, half-life may be prolonged to up to 12 hours, requiring dose adjustment |
| Protein binding | Highly protein bound (95-98%), primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.15-0.25 L/kg, indicating limited extravascular distribution; primarily confined to plasma and interstitial fluid. |
| Bioavailability | Oral bioavailability is 50-60% due to first-pass metabolism; topical bioavailability is negligible systemically (<2%). |
| Onset of Action | Oral: 30-45 minutes; Topical: 2-4 hours; Intravenous: 5-10 minutes. |
| Duration of Action | Duration is 6-8 hours after oral or IV administration; topical effects persist for 12-24 hours due to sustained local concentration. |
| Action Class | Anti Pigmentation & Skin lightening agent |
| Brand Substitutes | Genquin Cream, Albaquin 20% Cream |
Topical cream applied to affected areas twice daily. Do not exceed 45 g per month.
| Dosage form | CREAM |
| Renal impairment | No adjustment required. Drug is minimally absorbed; systemic effect negligible. |
| Liver impairment | No adjustment required. Minimal hepatic metabolism. |
| Pediatric use | Safety and efficacy in children under 12 years have not been established; use not recommended. |
| Geriatric use | No specific adjustments; use with caution in patients with pre-existing skin conditions or impaired wound healing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BENOQUIN (BENOQUIN).
| Breastfeeding | It is not known if hydroquinone is excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio available. |
| Teratogenic Risk | BENOQUIN (hydroquinone) is categorized as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at doses 5-10 times the human dose, but no adequate human studies exist. Risk cannot be ruled out; use only if benefit justifies potential risk to fetus. Avoid in first trimester if possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to quinolones; history of tendon disorders with fluoroquinolones; children (<18 years), pregnancy, lactation.
| Precautions | Photosensitivity; may cause tendon damage; peripheral neuropathy; CNS effects (seizures, dizziness); caution in elderly and renal impairment. |
| Food/Dietary | No known food interactions. Avoid sun exposure; no specific dietary restrictions. |
| Clinical Pearls | BENOQUIN (monobenzone) is used for depigmentation in patients with extensive vitiligo. It irreversibly destroys melanocytes; apply strictly to hyperpigmented areas only. Test for allergic contact dermatitis before use. Avoid sun exposure; use broad-spectrum sunscreen. Depigmentation may take 1-4 months; permanent. Not for use on nevi or lentigines. |
Loading safety data…
| Fetal Monitoring | Monitor for skin irritation, allergic reactions, and ochronosis. No specific fetal monitoring required; however, consider fetal ultrasound if used during pregnancy. |
| Fertility Effects | No human data on fertility effects. Animal studies have not shown impaired fertility at therapeutic doses. |
| Patient Advice | Apply only to hyperpigmented patches; avoid normal skin. Use gloves or applicator. · Do not use on moles, freckles, or sun spots; permanent depigmentation may occur. · Perform a patch test on a small area for 24-48 hours before full application. · Avoid direct sunlight and use high-SPF sunscreen daily. · Depigmentation is permanent; consider cosmetic implications. · Do not use during pregnancy or breastfeeding unless directed by physician. · Keep out of reach of children; for external use only. |